2016 American Transplant Congress
Clinical, Histologic and Charge Endpoints When Populations with Hepatitis C Recurrence Are Treated with Direct-Acting Antiviral or Interferon Based Therapies.
University of Kansas, Kansas City, KS.
Background: While the primary endpoint for patients transplanted for Hepatitis C (HCV) has been established as sustained virologic response (SVR), different pathways have existed to…2016 American Transplant Congress
Utilization of HCV-Positive Donors' Kidneys: Potential Benefits in the Era of Direct Acting Antiviral (DAA) Therapy.
Organ shortage and expanding kidney waiting list fostered utilization of HCV positive donors' organs (HCVD+). HCVD+ kidneys have slightly worse long term outcomes compared with…2016 American Transplant Congress
Utilization and Discard of HCV+ Donor Livers in the Advent of Direct-Acting Antiviral Therapy.
While 45% of liver candidates are hepatitis C (HCV)-antibody positive (+) and might benefit from a HCV+ donor liver, only a small proportion receive one.…2016 American Transplant Congress
Direct-Acting Antivirals for Hepatitis C Treatment in Kidney Transplant Recipients.
University of Minnesota, Minneapolis.
Background: Hepatitis C infection is associated with worse clinical outcomes in kidney transplant recipients. Direct-acting antivirals (DAAs) have been effectively used in liver transplant patients…2016 American Transplant Congress
Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection.
Background and Aims: Interferon (IFN) and ribavirin (RBV) for the treatment of chronic hepatitis C (HCV) in kidney transplant recipients is complicated by the risk…2016 American Transplant Congress
High Efficacy of Ledipasvir/Sofosbuvir with Ribavirin in HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials.
Introduction: HCV infected patients with decompensated liver disease have significant morbidity & mortality. The efficacy & safety of LDV/SOF + RBV was evaluated in a…2016 American Transplant Congress
Tacrolimus Levels in Patients Treated with Direct Acting Antivirals Post-Transplant.
Pharmacy, Oregon Health & Science University, Portland, OR.
Purpose: To determine if treatment of recurrent hepatitis C virus (HCV) post-liver transplant with the direct-acting antivirals (DAAs) sofosbuvir, simeprevir, and ledipasvir (in combination and/or…2016 American Transplant Congress
Short Duration Perioperative Administration of Ledipasvir/Sofosbuvir Is Safe and Effective in Preventing HCV Recurrence After Liver Transplant.
Background:The optimal timing and duration of DAA therapy in HCV patients undergoing liver transplant(LT) is unknown. CRUSH-C is an open-label, Phase 2 study evaluating the…2016 American Transplant Congress
Time Course of Hepatic Graft Function Improvement After Ledipasivir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR.
Background: In SOLAR-1, liver transplant recipients with HCV and either fibrosis or cirrhosis were treated at baseline with ledipasvir/sofosbuvir and ribavirin for 12 or 24…2016 American Transplant Congress
Hepatitis C Eradication with Sofosbuvir Based Regimens Leads to Significant Metabolic Changes in Post Orthotopic Liver Transplant Patients.
The purpose of this study was to assess the effect of hepatitis C virus (HCV) eradication with sofosbuvir based regimens on glycemic and lipid control…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- 28
- Next Page »